Lexicon Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: LXRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Lexicon Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Lexicon Pharmaceuticals generated -$9.2 million of operating cash flow. That left free cash flow of -$9.2 million, a free-cash-flow margin of -1328.3% of revenue. Free cash flow was down 154.1% from the prior year's $17.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
Lexicon Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -31.77M | -1.04M | -15.53M | -12.77M | 3.25M | -25.30M | -33.77M | -64.81M | -53.43M | -48.40M | -49.76M | -50.52M |
| Net Income growth (YoY) | -1077.09% | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 102.00K | 110.00K | 118.00K | 151.00K | 176.00K | 176.00K | 125.00K | 126.00K | 139.00K | 144.00K | 147.00K | 151.00K |
| Stock-Based Compensation | 3.34M | 3.08M | 2.83M | 3.44M | 3.19M | 3.04M | 1.54M | 2.80M | 4.86M | 4.30M | 3.21M | 3.90M |
| Change in Working Capital | 14.32M | -16.09M | -5.63M | -13.95M | 11.61M | -20.45M | 9.59M | 8.72M | 4.92M | -9.59M | -3.31M | 6.14M |
| Operating Cash Flow | -9.19M | -14.73M | -17.23M | -23.83M | 16.99M | -43.78M | -21.49M | -53.62M | -48.54M | -55.13M | -50.55M | -41.62M |
| Capital Expenditures | — | — | 0 | 0 | — | — | -474.00K | -307.00K | -250.00K | 0 | 0 | -83.00K |
| Investing Cash Flow | -16.46M | -70.26M | 4.83M | 52.13M | 15.48M | 40.58M | 53.70M | 53.47M | -12.32M | -110.22M | 51.90M | -39.33M |
| Share Repurchases | — | — | — | — | — | — | 0 | 0 | 0 | -1.73M | 0 | 0 |
| Debt Issued | — | — | — | — | — | — | 0 | 0 | — | — | -1.00K | 1.00K |
| Debt Repaid | -54.26M | -5.00M | -3.00M | 0 | -45.00M | 0 | 0 | 0 | — | — | — | — |
| Financing Cash Flow | -512.00K | 88.76M | -2.93M | 0 | -45.00M | -572.00K | -104.00K | -916.00K | -14.00K | 239.38M | -1.00K | -210.00K |
| Net Change in Cash | -26.16M | 3.76M | -15.33M | 28.29M | -12.52M | -3.77M | 32.10M | -1.07M | -60.88M | 74.03M | 1.35M | -81.16M |
| Free Cash Flow | -9.19M | -14.73M | -17.23M | -23.83M | 16.99M | -43.78M | -21.96M | -53.93M | -48.79M | -55.13M | -50.55M | -41.70M |
This table shows 12 quarterly periods of Lexicon Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow LXRX's reporting calendar. What is a cash flow statement?